• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

结直肠癌中Kras基因第12密码子存在两种不同突变:支持肿瘤异质性概念的病例报告

Coexistence of two different mutations in codon 12 of the Kras gene in colorectal cancer: Report of a case supporting the concept of tumoral heterogeneity.

作者信息

Improta Giuseppina, Zupa Angela, Possidente Luciana, Tartarone Alfredo, Pedicini Piernicola, Nappi Antonio, Molinari Sergio, Fraggetta Filippo, Vita Giulia

机构信息

Laboratory of Clinical Research and Molecular Diagnostics, IRCCS-CROB Hospital, Rionero In Vulture, Potenza;

出版信息

Oncol Lett. 2013 May;5(5):1741-1743. doi: 10.3892/ol.2013.1255. Epub 2013 Mar 14.

DOI:10.3892/ol.2013.1255
PMID:23761841
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3678636/
Abstract

Evaluation of the mutational status of KRAS is a crucial step for the correct therapeutic approach in treating advanced colorectal cancer as the identification of wild-type KRAS tumors leads to more specific and less toxic treatments for patients. Although several studies have highlighted the differences between primary and metastatic tumors, the possibility of two or more mutations in the same codon has seldom been reported. The present study reports an additional case of an advanced adenocarcinoma of the colon showing two somatic mutations (p.G12D and p.G12V) in the same codon (codon 12) of exon 2 of the KRAS gene, thus supporting the possibility of two differing clonal origins of the tumor. Although the clinical significance of multiple mutations remains unknown at present, based on the limited data available in the literature, this rare event appears to be associated with a more aggressive disease, as in the present case. This case report demonstrates the existence of intratumoral heterogeneity and the coexistence of distinct clones within a tumor that may have profound clinical implications for disease progression and therapeutic responses.

摘要

评估KRAS的突变状态是晚期结直肠癌正确治疗方法的关键步骤,因为野生型KRAS肿瘤的鉴定可为患者带来更具特异性且毒性更小的治疗。尽管多项研究强调了原发性肿瘤和转移性肿瘤之间的差异,但同一密码子出现两个或更多突变的可能性鲜有报道。本研究报告了另一例晚期结肠腺癌病例,该病例在KRAS基因第2外显子的同一密码子(密码子12)处显示出两个体细胞突变(p.G12D和p.G12V),从而支持了肿瘤存在两种不同克隆起源的可能性。尽管目前多个突变的临床意义尚不清楚,但根据文献中的有限数据,这种罕见事件似乎与更具侵袭性的疾病有关,就像本病例一样。本病例报告证明了肿瘤内异质性以及肿瘤内不同克隆的共存,这可能对疾病进展和治疗反应具有深远的临床意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2a0/3678636/da89238881ab/OL-05-05-1741-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2a0/3678636/da89238881ab/OL-05-05-1741-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2a0/3678636/da89238881ab/OL-05-05-1741-g00.jpg

相似文献

1
Coexistence of two different mutations in codon 12 of the Kras gene in colorectal cancer: Report of a case supporting the concept of tumoral heterogeneity.结直肠癌中Kras基因第12密码子存在两种不同突变:支持肿瘤异质性概念的病例报告
Oncol Lett. 2013 May;5(5):1741-1743. doi: 10.3892/ol.2013.1255. Epub 2013 Mar 14.
2
Coexistence of and Mutations in Colorectal Cancer: A Case Report Supporting The Concept of Tumoral Heterogeneity.结直肠癌中KRAS和NRAS突变共存:支持肿瘤异质性概念的一例报告
Cell J. 2017 Spring;19(Suppl 1):113-117. doi: 10.22074/cellj.2017.5123. Epub 2017 May 17.
3
Not all mutations of predict poor prognosis in patients with colorectal cancer.并非所有的[具体基因名称未给出]突变都预示着结直肠癌患者预后不良。
Int J Clin Exp Pathol. 2019 Mar 1;12(3):957-967. eCollection 2019.
4
Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.分析循环DNA和蛋白质生物标志物以预测瑞戈非尼的临床活性并评估转移性结直肠癌患者的预后:CORRECT试验的回顾性探索性分析
Lancet Oncol. 2015 Aug;16(8):937-48. doi: 10.1016/S1470-2045(15)00138-2. Epub 2015 Jul 13.
5
Mutations in KRAS codon 12 predict poor survival in Chinese patients with metastatic colorectal cancer.KRAS基因第12密码子的突变预示着中国转移性结直肠癌患者的生存率较低。
Oncol Lett. 2018 Mar;15(3):3161-3166. doi: 10.3892/ol.2017.7709. Epub 2017 Dec 28.
6
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.KRAS p.G13D 突变与西妥昔单抗治疗化疗耐药转移性结直肠癌患者结局的相关性。
JAMA. 2010 Oct 27;304(16):1812-20. doi: 10.1001/jama.2010.1535.
7
Molecular Characterization of KRAS, BRAF, and EGFR Genes in Cases with Prostatic Adenocarcinoma; Reporting Bioinformatics Description and Recurrent Mutations.前列腺腺癌病例中KRAS、BRAF和EGFR基因的分子特征;报告生物信息学描述和复发性突变
Clin Lab. 2015;61(7):749-59. doi: 10.7754/clin.lab.2014.141210.
8
G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab.G12V和G12A KRAS突变与接受贝伐单抗治疗的转移性结直肠癌患者的不良预后相关。
Tumour Biol. 2016 May;37(5):6823-30. doi: 10.1007/s13277-015-4523-7. Epub 2015 Dec 10.
9
Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.常规诊断分析转移性结直肠癌中 KRAS 突变的频率和类型。
Pathol Res Pract. 2009;205(12):858-62. doi: 10.1016/j.prp.2009.07.010. Epub 2009 Aug 12.
10
[KRAS gene mutation in colorectal cancer].[结直肠癌中的KRAS基因突变]
Rev Med Chil. 2013 Sep;141(9):1166-72. doi: 10.4067/S0034-98872013000900009.

引用本文的文献

1
Same-Cell Co-Occurrence of RAS Hotspot and BRAF V600E Mutations in Treatment-Naive Colorectal Cancer.治疗初治结直肠癌中 RAS 热点和 BRAF V600E 突变的同细胞共发生。
JCO Precis Oncol. 2022 Mar;6:e2100365. doi: 10.1200/PO.21.00365.
2
Silencing of Oncogenic KRAS by Mutant-Selective Small Interfering RNA.通过突变体选择性小干扰RNA沉默致癌性KRAS
ACS Pharmacol Transl Sci. 2021 Feb 4;4(2):703-712. doi: 10.1021/acsptsci.0c00165. eCollection 2021 Apr 9.
3
High Intra- and Inter-Tumoral Heterogeneity of RAS Mutations in Colorectal Cancer.

本文引用的文献

1
Correlation between EGFr expression and accelerated proliferation during radiotherapy of head and neck squamous cell carcinoma.头颈部鳞状细胞癌放疗过程中 EGFr 表达与加速增殖的相关性。
Radiat Oncol. 2012 Aug 24;7:143. doi: 10.1186/1748-717X-7-143.
2
Modelling the correlation between EGFr expression and tumour cell radiosensitivity, and combined treatments of radiation and monoclonal antibody EGFr inhibitors.模拟表皮生长因子受体(EGFr)表达与肿瘤细胞放射敏感性之间的相关性,以及放射治疗与单克隆抗体EGFr抑制剂的联合治疗。
Theor Biol Med Model. 2012 Jun 19;9:23. doi: 10.1186/1742-4682-9-23.
3
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.
结直肠癌中RAS突变的高度肿瘤内和肿瘤间异质性
Int J Mol Sci. 2016 Dec 1;17(12):2015. doi: 10.3390/ijms17122015.
4
Oncogene Mutations in Colorectal Polyps Identified in the Norwegian Colorectal Cancer Prevention (NORCCAP) Screening Study.挪威结直肠癌预防(NORCCAP)筛查研究中鉴定出的结直肠息肉中的癌基因突变。
Clin Med Insights Pathol. 2016 Sep 7;9:19-28. doi: 10.4137/CPath.s40143. eCollection 2016.
5
Novel KRAS gene mutations in sporadic colorectal cancer.散发性结直肠癌中的新型KRAS基因突变
PLoS One. 2014 Nov 20;9(11):e113350. doi: 10.1371/journal.pone.0113350. eCollection 2014.
6
Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.结直肠癌生物标志物检测更新指南:西班牙病理学会和西班牙医学肿瘤学会的全国共识
Clin Transl Oncol. 2015 Apr;17(4):264-73. doi: 10.1007/s12094-014-1252-0. Epub 2014 Nov 6.
7
Genome-wide mutational landscape of mucinous carcinomatosis peritonei of appendiceal origin.阑尾来源腹膜黏液性癌的全基因组突变图谱。
Genome Med. 2014 May 29;6(5):43. doi: 10.1186/gm559. eCollection 2014.
多区域测序揭示的肿瘤内异质性和分支进化。
N Engl J Med. 2012 Mar 8;366(10):883-892. doi: 10.1056/NEJMoa1113205.
4
Multiple mutations in the Kras gene in colorectal cancer: review of the literature with two case reports.结直肠癌中 Kras 基因的多种突变:文献复习并附两例报告。
Int J Colorectal Dis. 2011 Oct;26(10):1241-8. doi: 10.1007/s00384-011-1238-0. Epub 2011 May 21.
5
Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls.常规实践中的转移性结直肠癌 KRAS 基因分型:结果和陷阱。
Mod Pathol. 2011 Aug;24(8):1090-100. doi: 10.1038/modpathol.2011.60. Epub 2011 Apr 22.
6
Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing.晚期结直肠癌(aCRC)患者肿瘤内 KRAS 和 BRAF 突变状态的异质性及多次样本检测的成本效益。
Anal Cell Pathol (Amst). 2011;34(1-2):61-6. doi: 10.3233/ACP-2011-0005.
7
A gene expression signature for chemoradiosensitivity of colorectal cancer cells.结直肠癌细胞放化疗敏感性的基因表达特征。
Int J Radiat Oncol Biol Phys. 2010 Nov 15;78(4):1184-92. doi: 10.1016/j.ijrobp.2010.06.023.
8
Patient with colorectal cancer with heterogeneous KRAS molecular status responding to cetuximab-based chemotherapy.患有结直肠癌且KRAS分子状态异质性的患者对基于西妥昔单抗的化疗有反应。
J Clin Oncol. 2010 Dec 20;28(36):e756-8. doi: 10.1200/JCO.2010.30.5011. Epub 2010 Sep 20.
9
Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis.结直肠癌转移进展过程中获得的 KRAS 突变:对治疗和预后的可能影响。
Cancer Chemother Pharmacol. 2010 Aug;66(3):605-9. doi: 10.1007/s00280-010-1298-9. Epub 2010 Apr 2.
10
Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases.原发结直肠腺癌及其转移灶中 KRAS、BRAF 和 PIK3CA 基因突变的流行率和异质性。
Clin Cancer Res. 2010 Feb 1;16(3):790-9. doi: 10.1158/1078-0432.CCR-09-2446. Epub 2010 Jan 26.